Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway 
by targeting EGFR

Li,Bin; Ding,Cui-Min; Li,Yan-Xiao; Peng,Jing-Cui; Geng,Nan; Qin,Wen-Wen

doi:10.3892/or.2018.6215

Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR

Authors:
- Bin Li
- Cui-Min Ding
- Yan-Xiao Li
- Jing-Cui Peng
- Nan Geng
- Wen-Wen Qin
View Affiliations

Affiliations: Department of Respiratory Medicine, Fourth Hospital of Hebei Medical University, Hebei 050011, P.R. China, Department of Respiratory Medicine, First Hospital of Shijiazhuang, Hebei 050011, P.R. China
Published online on: January 15, 2018 https://doi.org/10.3892/or.2018.6215
Pages: 1227-1234

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study determined the anticancer activity and its mechanism of microRNA‑133b on cell proliferation of cisplatin-induced non-small cell lung cancer cells. The expression of microRNA-133b cisplatin‑induced non-small cell lung cancer (NSCLC) tissue was lower than that of para-carcinoma tissue in patients. Overall survival of higher expression in cisplatin-induced NSCLC patients was higher than that of lower expression in cisplatin‑induced NSCLC patients. Over-regulation of microRNA-133b inhibited cell proliferation and LDH activity, induced apoptosis and caspase-3 activity, suppressed the protein expression of EGFR, PI3K, p-Akt, p-JAK2 and p-STAT3, decreased cyclin D1 and increased Bax protein expression in cisplatin‑induced A549 cells. EGFR inhibitor (lapatinib) suppressed EGFR protein expression, inhibited cell proliferation and LDH activity, and induced apoptosis and caspase-3 activity in cisplatin-induced A549 cells by over-regulation of microRNA-133b. When EGFR protein expression was suppressed, PI3K, p-Akt, p-JAK2 and p-STAT3, decreased cyclin D1 and increased Bax protein expression in cisplatin-induced A549 cells by over-regulation of microRNA-133b. Altogether, our results indicated that over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced NSCLC by PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.

View Figures

View References

1	Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, et al Intergroupe Francophone de Cancérologie Thoracique (IFCT), : High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther. 11:1203–1213. 2012. View Article : Google Scholar : PubMed/NCBI
2	Shao M, Jin B, Niu Y, Ye J, Lu D and Han B: Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Cell Biochem Biophys. 70:1227–1237. 2014. View Article : Google Scholar : PubMed/NCBI
3	Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M and Gandara DR: Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 26:3351–3357. 2008. View Article : Google Scholar : PubMed/NCBI
4	Zhang Z, Xiao Y, Zhao J, Chen M, Xu Y, Zhong W, Xing J and Wang M: Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer. Respirology. 21:519–525. 2016. View Article : Google Scholar : PubMed/NCBI
5	Matsumoto M, Nakajima W, Seike M, Gemma A and Tanaka N: Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Biochem Biophys Res Commun. 473:490–496. 2016. View Article : Google Scholar : PubMed/NCBI
6	Dong Z, Zhong Z, Yang L, Wang S and Gong Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
7	Nishijima N, Seike M, Soeno C, Chiba M, Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K and Gemma A: miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. Int J Oncol. 48:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
8	Cui J, Mo J, Luo M, Yu Q, Zhou S, Li T, Zhang Y and Luo W: c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer. Int J Clin Exp Pathol. 8:12400–12409. 2015.PubMed/NCBI
9	Yi Y, Lu X, Chen J, Jiao C, Zhong J, Song Z, Yu X and Lin B: Downregulated miR-486-5p acts as a tumor suppressor in esophageal squamous cell carcinoma. Exp Ther Med. 12:3411–3416. 2016. View Article : Google Scholar : PubMed/NCBI
10	Luo J, Li H and Zhang C: MicroRNA-7 inhibits the malignant phenotypes of non-small cell lung cancer in vitro by targeting Pax6. Mol Med Rep. 12:5443–5448. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhang L, Qian J, Qiang Y, Huang H, Wang C, Li D and Xu B: Down-regulation of miR-4500 promoted non-small cell lung cancer growth. Cell Physiol Biochem. 34:1166–1174. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY and Jiang B: JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer. 73:366–374. 2011. View Article : Google Scholar : PubMed/NCBI
13	Guerriero I, D'Angelo D, Pallante P, Santos M, Scrima M, Malanga D, De Marco C, Ravo M, Weisz A, Laudanna C, et al: Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells. Oncotarget. 8:19172–19191. 2017. View Article : Google Scholar : PubMed/NCBI
14	Jiang J, Feng X, Zhou W, Wu Y and Yang Y: MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway. Oncotarget. 7:73188–73199. 2016. View Article : Google Scholar : PubMed/NCBI
15	Fang Y, Zhang C, Wu T, Wang Q, Liu J and Dai P: Transcriptome sequencing reveals key pathways and genes associated with cisplatin resistance in lung adenocarcinoma A549 Cells. PLoS One. 12:e01706092017. View Article : Google Scholar : PubMed/NCBI
16	Checinska A, Hoogeland BS, Rodriguez JA, Giaccone G and Kruyt FA: Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: A small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. Exp Cell Res. 313:1215–1224. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, Bankson J, Gao B, Girard L, Minna JD, Roth JA, et al: The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 66:9682–9690. 2006. View Article : Google Scholar : PubMed/NCBI
18	Fang C, Chen YX, Wu NY, Yin JY, Li XP, Huang HS, Zhang W, Zhou HH and Liu ZQ: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Sci Rep. 7:403842017. View Article : Google Scholar : PubMed/NCBI
19	Chen Y, Zhang Y, He J, Fu Y, Lin C and Li X: MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer. Oncol Rep. 37:1646–1652. 2017. View Article : Google Scholar : PubMed/NCBI
20	Chen J, Lan T, Zhang W, Dong L, Kang N, Zhang S, Fu M, Liu B, Liu K and Zhan Q: Feed-forward reciprocal activation of PAFR and STAT3 regulates epithelial-mesenchymal transition in non-small cell lung cancer. Cancer Res. 75:4198–4210. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, et al: VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 34:3107–3119. 2015. View Article : Google Scholar : PubMed/NCBI
22	Hu Y, Hong Y, Xu Y, Liu P, Guo DH and Chen Y: Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis. 19:1627–1636. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zhou W, Bi X, Gao G and Sun L: miRNA-133b and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling pathway in human renal carcinoma cells. Biomed Pharmacother. 84:722–729. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zhao Q, Yue J, Zhang C, Gu X, Chen H and Xu L: Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC). Oncotarget. 6:29335–29346. 2015. View Article : Google Scholar : PubMed/NCBI
25	Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X, Peng L, Sun J and Chen Z: miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. Int J Oncol. 48:1855–1867. 2016. View Article : Google Scholar : PubMed/NCBI
26	Xu Z, Liu D, Fan C, Luan L, Zhang X and Wang E: DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT/AP-1 pathway. Mol Carcinog. 53:917–925. 2014. View Article : Google Scholar : PubMed/NCBI
27	Sin TK, Wang F, Meng F, Wong SC, Cho WC, Siu PM, Chan LW and Yung BY: Implications of microRNAs in the treatment of gefitinib-resistant non-small cell lung cancer. Int J Mol Sci. 17:2372016. View Article : Google Scholar : PubMed/NCBI
28	Zhu Q, Liang X, Dai J and Guan X: Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway. Int J Clin Exp Pathol. 8:9175–9181. 2015.PubMed/NCBI